Skip to content
‹ Back to IndustriesSciences

SupplySide West 2021: CEO Insights

Deerland Probiotics and Enzymes, led by CEO Scott Ravitch, participated in Supply Side West 2021 to reconnect with industry stakeholders. The company showcased innovative products like Pre4 Pro and DE111, supported by clinical studies. Deerland continues to expand its product portfolio and scientific research, offering customer-centric solutions.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · DeerlandEnzymesProbioticSupplyside West
Share
SupplySide West 2021: CEO Insights

Key takeaways

01

Deerland introduced Pre4 Pro, a prebiotic effective in small quantities without causing digestive discomfort.

02

DE111 probiotic benefits digestive health and immunity, usable in various forms including gummies and kombucha.

03

Deerland's focus includes conducting clinical studies and co-creating formulations with customers.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Deerland Probiotics and Enzymes, led by CEO Scott Ravitch, is thrilled to be back at Supply Side West in Las Vegas. This prestigious trade show is a crucial event for the company, providing an opportunity to reconnect with important customers, prospective clients, suppliers, and industry professionals. With a focus on branded clinical products, Deerland Probiotics and Enzymes is showcasing innovative solutions that make a measurable difference in people’s lives.

One of the standout products is Pre4 Pro, a unique prebiotic that works effectively in small quantities, just 15 milligrams. Unlike mainstream prebiotics, Pre4 Pro doesn’t cause digestive discomfort. Additionally, the flagship DE111 probiotic offers tremendous benefits for digestive well-being and immunity. This versatile probiotic finds applications in various forms, from traditional supplements like capsules and tablets to more exciting options such as gummies, kombuchas, and food and beverage products. Another highlight is Solarplast, a potent antioxidant product that contributes to beauty from within. All these offerings are backed by robust human clinical studies, a testament to Deerland’s commitment to science and substantiated claims.

Over the past two years, Deerland Probiotics and Enzymes has made remarkable progress despite the challenges posed by the COVID-19 pandemic. The company has focused on conducting clinical studies and expanding its product portfolio. With six completed studies, including a groundbreaking germination study for DE111, Deerland has solid scientific evidence to support its offerings. They have also continued new product development, introducing Munispor for immune health and having three more products in the pipeline for launch. The integration of the Bifidin acquisition in 2019 has further enriched Deerland’s capabilities.

Looking ahead to 2021 and beyond, Deerland Probiotics and Enzymes remains committed to providing competitive differentiation and delivering exceptional value to its customers. By offering consultative solutions, the company goes beyond being an ingredients or manufacturing provider. Their team takes the time to understand customers’ goals and consumer needs, co-creating the best formulations for their products. This customer-centric approach has enabled Deerland’s partners to launch successful brands and attract new customers. The company’s culture, rooted in core values and a mission to make a measurable difference in people’s lives, serves as a guiding force in every decision and action.

Deerland Probiotics and Enzymes is dedicated to advancing science, expanding their portfolio, and building strong partnerships. With an unwavering commitment to quality, performance, and safety, they create innovative solutions that address emerging market needs. The company is grateful for the trust and faith that customers place in them and takes pride in the positive impact their products and services have on people’s lives.

Join Deerland Probiotics and Enzymes on their mission to make a measurable difference in the quality of people’s lives. Experience their scientific expertise, consultative approach, and commitment to excellence.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox projects the quantum cascade laser market to grow 8% to 12% a year through 2035, linking the outlook to faster adoption of mid-infrared spectroscopy in process control, environmental monitoring and pharmaceutical QA. It says QCLs win on high spectral brightness and room-temperature operation in compact form factors, and that the installed base of analytical instruments is growing.

  • 01Roughly one in three quantum cascade lasers shipped in 2030 is projected to replace equipment already in service, so maintenance calendars will set a growing share of demand.
  • 02For a plant or QA lab running QCL-based analyzers, the useful question is which laser maker sits inside each instrument and whether a second source exists.
  • 03Analyzers bought on a three-to-five-year cycle in 2026 come due between 2029 and 2031. Those years will show whether the forecast replacement wave turns up in real orders.

Oct 26, 2026

Why shared auto-injectors keep forcing rebuilt device files

Why shared auto-injectors keep forcing rebuilt device files

Vertex Knight co-founder Fubin Wu cites digitalization, personalization and large-volume delivery as trends reshaping drug delivery devices, arguing structured data can enable reuse and cut duplicated design-file work for shared auto-injectors. ISPE says no regulatory pathway exists for platform devices, and ONdrugDelivery counts 182 large-volume subcutaneous biologics, about 15% of IV and SC agents.

  • 01A device shared across drug products still triggers repeated design control work for each new combination product, and ISPE's November 2025 article says no regulatory pathway yet exists to approve a platform device.
  • 02FDA's May 2024 draft platform technology designation under section 506K is written for drug product applications, so device design files sit outside it.
  • 03Large-volume subcutaneous biologics above 2 mL numbered 182 in a January 2025 ONdrugDelivery review, about 15% of IV and SC agents; Advanced Drug Delivery Reviews reported in July 2026 that volumes up to 25 mL are now pursued.

Oct 22, 2026

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's Pingshan prefilled syringe plant in Shenzhen won the Innovation (Novel Technology) category at ISPE's 2026 Facility of the Year Awards. In the transcript ISPE posted with its podcast, CaiXue Wei describes vertical design, AGV-assisted transfer, AI inspection and 5G-MEC as one integrated system built around a 330 million-syringe annual capacity; Hepalink's own release adds a 24-meter warehouse, sub-10 millisecond 5G and 24,000-unit-an-hour inspection.

  • 01Hepalink's 24-meter automated warehouse raised space utilization 52 percent over a traditional layout on a land-scarce Shenzhen site supporting 330 million syringes a year.
  • 02AGVs pass material through vaporized hydrogen peroxide chambers straight into Grade A isolators, and Hepalink credits the zero-touch flow for a 100 percent first media fill.

Oct 22, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

CEO at Deerland Probiotics and Enzymes

Scott Ravitch is the CEO of Deerland Probiotics and Enzymes. He leads the company in providing innovative probiotic and enzyme solutions backed by robust clinical studies. Under his leadership, the company has focused on expanding its product portfolio and scientific research.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512